Navigation Links
Making treatment of rare blood disorder more affordable and effective
Date:2/27/2014

PHILADELPHIA A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system called "complement" -- that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.

Complement is a network of more than 50 proteins in the blood and on cell surfaces that quietly cruise the body, keeping a low profile until triggered into action. On the other hand, this system can turn, contributing to a broad spectrum of immune, inflammatory, and age-related diseases.

John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine, studies this early-warning system and how to correct it when its response goes overboard.

This is known to be the case with paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hematological disorder, which is estimated to affect between 1 and 5 per million people. In PNH, defective expression of regulatory proteins on the surface of blood cells leaves them vulnerable to complement attack. This can lead to premature death of the red blood cells, a process called hemolysis, which clinically results in severe anemia and contributes to a high risk of clotting.

Lambris and Daniel Ricklin, PhD, research assistant professor of Pathology and Laboratory Medicine, are developing novel therapeutics to tame this inappropriate complement activation and protect cell surfaces from attack.

Eculizumab (Soliris, an Alexion Pharmaceuticals drug) -- to date the only approved therapeutic for PNH -- reduces hemolysis and gives relief from blood transfusions for most PNH patients. However,
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brain Changes May Hamper Decision-Making in Old Age
2. OHSU Oregon National Primate Research Center develops new, safer method for making vaccines
3. After 25 years, World No Tobacco Day is making an impact
4. Making bad worse for expectant mothers
5. DotComSecrets’ Russell Brunson Is Revealing Online Money Making Secrets in Free Webinars for Students
6. New Electronic Cigarette Free Trial Kit Adds More Years to Smokers Life by Making it Easy to Quit Smoking
7. First Is Viewed as Best When Making Quick Decisions
8. Neuroeconomics to study decision-making in anxious individuals
9. Making it easier to learn to read
10. The making and unmaking of stem-like, aggressive breast cancer cells
11. UH students spent summer making a difference with hands-on research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... The Residential Senior Care Franchises ... years. The industry, which provides residential and personal-care services ... for themselves, has boomed on account of the aging ... seniors with memory impairment. As a result, IBISWorld expects ... 4.1% to $1.9 billion over the five years to ...
(Date:4/18/2015)... Carinsurancehints.com has released a new blog post explaining how to ... against fire damage. , Clients can now find auto ... is set intentionally on fire. This type of damages can ... things. , It is possible to compare the best ... , in just a few minutes. Clients should always ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... New York, New York (PRWEB) April 18, 2015 ... http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) filed on behalf of individuals who ... hip replacement system continue to move forward in the ... an Order dated April 10th, the Court has amended ... joinder of unrelated cases. Among other things, the new ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
Breaking Medicine News(10 mins):Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Online Auto Insurance Quotes For Plans That Cover Fire Damages! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2
... finds , THURSDAY, June 11 (HealthDay News) -- Mad cow ... somehow goes astray and deprives the healthy brain cells of ... considered a prion disease because it has been found to ... is found on the surface of many cells -- including ...
... ... media age. , ... (Vocus) June 11, 2009 -- From cyberbullying and violent video games to social networking and ... To help parents navigate this new and changing landscape, the Center on Media and ...
... of the crime in cancer are guilty of the initiation and ... disease, a team led by scientists at The University of Texas ... Cancer Cell . "We have a smoking gun" that ... that makes them are abnormally expressed in many types of cancer, ...
... Wii may help treat symptoms of Parkinson,s disease, including ... Parkinson,s disease is a degenerative disease that impairs ... game console, which simulates various sports and activities, could ... found additional benefits as well. "The Wii allows ...
... fifth most common malignancy worldwide and the third leading ... been associated with HCC. However, the relationship between type ... the effects of antidiabetic therapy on HCC risk have ... led by Dr. Valter Donadon from Pordenone Hospital addressed ...
... common cancers in China. Although the association between the ... the relation between smoking, alcohol drinking, family history of ... still remains uncertain. So it is important to investigate ... sporadic colorectal cancer. A research team led by ...
Cached Medicine News:Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 3Health News:Researchers identify 4 new targets for breast cancer 2Health News:Wii-hab may enhance Parkinson's treatment 2
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for the treatment of central ... for the first quarter of 2015 on Wednesday, May ... The Company will host a conference call at 4:30 ... Vanda management will discuss the first quarter 2015 financial ...
(Date:4/16/2015)... April 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... 31, 2015 on Wednesday, May 6, 2015, following the close ... an investor conference call and live webcast on the same ... update and discuss the financial results.  To ... , under the "Investors" link.  Please log onto the webcast ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... on Valopicitabine Combined,with an Investigational Protease Inhibitor, ... Pharmaceuticals, Inc. today announced results from two ... valopicitabine (NM283) and,pegylated interferon alfa-2a (Pegasys(R)) in ... the genotype-1,strain of the hepatitis C virus ...
... /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that new ... (HDAC) inhibitor being,investigated for the treatment of ... the prevention of severe oral mucositis,will be ... Cancer,Research (AACR) 2007 Annual Meeting in Los ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: